scholarly journals Host-microbe cross-talk in the lung microenvironment: implications for understanding and treating chronic lung disease

2020 ◽  
pp. 1902320 ◽  
Author(s):  
Reinoud Gosens ◽  
Pieter S. Hiemstra ◽  
Ian M. Adcock ◽  
Ken R. Bracke ◽  
Robert P. Dickson ◽  
...  
Keyword(s):  
Microbial Community ◽  
Cross Talk ◽  
Respiratory Diseases ◽  
Human Microbiome ◽  
Targeted Therapeutics ◽  
Foreseeable Future ◽  
Prevention Strategies ◽  
Therapeutic Approaches ◽  
Chronic Respiratory Diseases ◽  
Holistic Approaches

Chronic respiratory diseases are highly prevalent worldwide and will continue to rise in the foreseeable future. Despite intensive efforts over the recent decades, the development of novel and effective therapeutic approaches has been slow. There is however new and increasing evidence that communities of microorganisms in our body, the human microbiome, are crucially involved in the development and progression of chronic respiratory diseases. Understanding the detailed mechanisms underlying this cross-talk between host and microbiota is critical for development of microbiome- or host-targeted therapeutics and prevention strategies. Here we review and discuss the most recent knowledge on the continuous reciprocal interaction between the host and microbes in health and respiratory disease. Furthermore, we highlight promising developments in microbiome-based therapies and discuss the need to employ more holistic approaches of restoring both the pulmonary niche and the microbial community.

scholarly journals Lung Microbiome in Asthma: Current Perspectives

2019 ◽  
Vol 8 (11) ◽  
pp. 1967 ◽  
Author(s):  
Konstantinos Loverdos ◽  
Georgios Bellos ◽  
Louiza Kokolatou ◽  
Ioannis Vasileiadis ◽  
Evangelos Giamarellos ◽  
...  
Keyword(s):  
Respiratory Diseases ◽  
Human Microbiome ◽  
Current Evidence ◽  
Host Immune System ◽  
Prevention Strategies ◽  
Chronic Respiratory Diseases ◽  
Lung Microbiome ◽  
Modes Of Interaction ◽  
Review Current

A growing body of evidence implicates the human microbiome as a potentially influential player actively engaged in shaping the pathogenetic processes underlying the endotypes and phenotypes of chronic respiratory diseases, particularly of the airways. In this article, we specifically review current evidence on the characteristics of lung microbiome, and specifically the bacteriome, the modes of interaction between lung microbiota and host immune system, the role of the “lung–gut axis”, and the functional effects thereof on asthma pathogenesis. We also attempt to explore the possibilities of therapeutic manipulation of the microbiome, aiming at the establishment of asthma prevention strategies and the optimization of asthma treatment.

Introduction to Chronic Respiratory Diseases: A Pressing Need for Novel Therapeutic Approaches

2021 ◽  
pp. 47-84
Author(s):  
Yinghan Chan ◽  
Sin Wi Ng ◽  
Hui Shan Liew ◽  
Lesley Jia Wei Pua ◽  
Laura Soon ◽  
...  
Keyword(s):  
Respiratory Diseases ◽  
Therapeutic Approaches ◽  
Chronic Respiratory Diseases ◽  
Novel Therapeutic

scholarly journals Epigenetic targets for therapeutic approaches in COPD and asthma. Nutrigenomics – possible or illusive

Folia Medica ◽  
2019 ◽  
Vol 61 (3) ◽  
pp. 358-369
Author(s):  
Radostina V. Cherneva ◽  
Dimitar Kostadinov
Keyword(s):  
Gene Expression ◽  
Chronic Exposure ◽  
Respiratory Diseases ◽  
Epigenetic Changes ◽  
Therapeutic Approaches ◽  
Control Of Gene Expression ◽  
Chronic Respiratory Diseases ◽  
Key Steps ◽  
Epigenetic Signatures ◽  
Affect Gene Expression

Oxidative stress generated by cigarette smoking, environmental pollution, or other noxious particles leads to epigenetic changes in the cells of the respiratory tract. They reflect cell adaptation in response to chronic exposure to external factors. Although there is no change in the genetic code, epigenetic changes may be heritable and translated from one generation to another, accumulating abnormalities and rendering cells into entirely different phenotype, causing disease. DNA methylation, post-translation histone modification, ubiquitination, sumoylation and miRNA transcriptional regulation are the major processes that are responsible for the epigenetic control of gene expression. All of them are reversible. They can be regulated by targeting specific enzymes/proteins involved in the process in order to mitigate inflammation. Chronic respiratory diseases have epigenetic signatures that affect gene expression in the lung. Targeting them provides the development of novel diagnostic and therapeutic approaches in respiratory medicine. Nutrigenomics reveals the beneficial effect of natural phytochemicals, affecting key steps in the signaling pathways of chronic respiratory diseases.

CRISPR/Cas9 Genome Editing Tool: A Promising Tool for Therapeutic Applications on Respiratory Diseases

2020 ◽  
Vol 20 (5) ◽  
pp. 333-346
Author(s):  
Sadiya Bi Shaikh ◽  
Yashodhar Prabhakar Bhandary
Keyword(s):  
Respiratory Diseases ◽  
Gene Editing ◽  
Epithelial Mesenchymal Transition ◽  
Respiratory Health ◽  
Chronic Obstructive ◽  
Therapeutic Tool ◽  
Obstructive Pulmonary Disease ◽  
Mesenchymal Transition ◽  
Chronic Respiratory Diseases ◽  
Promising Tool

Respiratory diseases are one of the prime topics of concern in the current era due to improper diagnostics tools. Gene-editing therapy, like Clustered regularly interspaced palindromic repeats- associated nuclease 9 (CRISPR/Cas9), is gaining popularity in pulmonary research, opening up doors to invaluable insights on underlying mechanisms. CRISPR/Cas9 can be considered as a potential gene-editing tool with a scientific community that is helping in the advancement of knowledge in respiratory health and therapy. As an appealing therapeutic tool, we hereby explore the advanced research on the application of CRISPR/Cas9 tools in chronic respiratory diseases such as lung cancer, Acute respiratory distress syndrome (ARDS) and cystic fibrosis (CF). We also address the urgent need to establish this gene-editing tool in various other lung diseases such as asthma, Chronic obstructive pulmonary disease (COPD) and Idiopathic pulmonary fibrosis (IPF). The present review introduces CRISPR/Cas9 as a worthy application in targeting epithelial-mesenchymal transition and fibrinolytic system via editing specific genes. Thereby, based on the efficiency of CRISPR/Cas9, it can be considered as a promising therapeutic tool in respiratory health research.

From Genesis To Revelation: The Role Of Inflammatory Mediators In Chronic Respiratory Diseases And Their Control By Nucleic Acid-Based Drugs

2016 ◽  
Vol 13 (999) ◽  
pp. 1-1 ◽  
Author(s):  
Sante Di Gioia ◽  
Carla Sardo ◽  
Stefano Castellani ◽  
Barbara Porsio ◽  
Giuliana Belgiovine ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
Inflammatory Mediators ◽  
Respiratory Diseases ◽  
Chronic Respiratory Diseases

Interleukin-17A: A Potential Therapeutic Target in Chronic Lung Diseases

2019 ◽  
Vol 19 (7) ◽  
pp. 921-928 ◽  
Author(s):  
Sadiya Bi Shaikh ◽  
Ashwini Prabhu ◽  
Yashodhar Prabhakar Bhandary
Keyword(s):  
Respiratory Diseases ◽  
Inflammatory Cytokine ◽  
Inflammatory Responses ◽  
Chronic Obstructive ◽  
Interleukin 17 ◽  
Potential Therapeutic Target ◽  
Chronic Respiratory Diseases ◽  
Chronic Lung Diseases ◽  
Interleukin 17A ◽  
Insight Into

Background: Interleukin-17A (IL-17A) is a pro-inflammatory cytokine that has gained a lot of attention because of its involvement in respiratory diseases. Interleukin-17 cytokine family includes six members, out of which, IL-17A participates towards the immune responses in allergy and inflammation. It also modulates the progression of respiratory disorders. Objective: The present review is an insight into the involvement and contributions of the proinflammatory cytokine IL-17A in chronic respiratory diseases like Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Distress (COPD), asthma, pneumonia, obliterative bronchiolitis, lung cancer and many others. Conclusion: IL-17A is a major regulator of inflammatory responses. In all the mentioned diseases, IL- 17A plays a prime role in inducing the diseases, whereas the lack of this pro-inflammatory cytokine reduces the severity of respective respiratory diseases. Thereby, this review suggests IL-17A as an instrumental target in chronic respiratory diseases.

Non-Communicable Diseases and Global Health Politics

2019 ◽  
pp. 626-659
Author(s):  
Roger Magnusson
Keyword(s):  
Respiratory Diseases ◽  
Communicable Diseases ◽  
World Health ◽  
Global Response ◽  
Non Communicable Diseases ◽  
Health Politics ◽  
Chronic Respiratory Diseases ◽  
Health Organization ◽  
High Level ◽  
And Control

Non-communicable diseases (NCDs), including cardiovascular disease, cancer, chronic respiratory diseases, and diabetes, are responsible for around 70 percent of global deaths each year. This chapter describes how NCDs have become prevalent and critically evaluates global efforts to address NCDs and their risk factors, with a particular focus on the World Health Organization (WHO) and United Nations (UN) system. It explores the factors that have prevented those addressing NCDs from achieving access to resources and a priority commensurate with their impact on people’s lives. The chapter evaluates the global response to NCDs both prior to and since the UN High-Level Meeting on Prevention and Control of Non-communicable Diseases, held in 2011, and considers opportunities for strengthening that response in future.

Sign in / Sign up

Export Citation Format

Share Document